ARCH Arch Biopartners Inc.

0.6152USD0.8800 CAD · TSXV-6.38%Mkt Cap: 41.79M USDP/E: —

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…